DRugwatch BlogRSS 2.0

DRugwatch Blog > January 2012

  • 1/20/2012 2:12:09 PM
    A New Era and Market Opportunity for Multaq
    Matt Kileen 1/19/2012 6:15:13 PM
    Paula Deen and Questioning Celebrity Drug Endorsements
    Contributor: Allison Thrower

    If time and tradition are any indicators, celebrity pharmaceutical endorsements will be an advertising trend for years to come...
  • 1/17/2012 4:47:06 PM
    The current shortage of Doxil across the major markets
    Matt Kileen 1/9/2012 8:04:20 PM
    Diabetes Drug Development: 2011 Year in Review and a Look Ahead Towards 2012 And Beyond – Part 2
    Matt Kileen 1/6/2012 5:25:06 PM
    Diabetes Drug Development: 2011 Year in Review and a Look Ahead Towards 2012 And Beyond – Part 1
    Matt Kileen

     

    rss twitter linkedin

     

    DRugwatch Blog

    Quick insight on intriguing drug market developments from Decision Resources’ analysts.

    Recent posts

    Post title:
    Sweet results for Contrave leave a bad taste in the mouth
    Post date:
    3/11/2015 11:26:21 AM
    Post Summary:

    Tim BlackstockContributor: Tim Blackstock
    Topics: Obesity, Contrave, Mysimba, Orexigen, FDA, Regulatory Approval, Cardiovascular Outcomes

    Orexigen has made interim data from the LIGHT study publically available in a financial report; details can be viewed here.
     


    Post title:
    Creating oral versions of injectable therapies for chronic diseases – a “win-win-win” concept
    Post date:
    3/6/2015 11:13:08 AM
    Post Summary:

    Stefanie MatlokContributor: Stefanie Hoffart
    Therapeutic area: Cardiovascular and Metabolic Disorders

    Novo Nordisk recently announced the first positive Phase 2 results for an oral GLP-1 analogue. Oral therapies are typically utilized in the early lines of therapy for type 2 diabetes, but as the disease progresses more aggressive treatment is required so patients can end up on multiple oral medications.


    Post title:
    Next Steps for Vorapaxar: EU PAD Label and Antidote Development?
    Post date:
    2/17/2015 10:49:37 AM
    Post Summary:

    Stefanie Matlok Graeme GreeneWriiten by: Stefanie Hoffart and Graeme Green

    Topic: Cardiovascular

    On January 19, 2015, the European Medicines Agency (EMA) approved the thrombin receptor antagonist vorapaxar (Merck’s Zontivity) for secondary prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI), co-administered with acetylsalicylic acid (ASA) and, if necessary, clopidogrel.


    Post title:
    Bococizumab: Late to Great? Dyslipidemia Déjà vu?
    Post date:
    2/12/2015 3:58:28 PM
    Post Summary:
    Tim BlackstockContributor: Tim Blackstock
    Topics: Cardiovascular

    The link between high low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) risk is well established, as is, the evidence showing that agents that reduce LDL-C can prevent CV events.

    Post title:
    Sandoz’s Biosimilar Filgrastim Scores Positive Recommendation from FDA Advisory Committee
    Post date:
    1/22/2015 3:44:26 PM
    Post Summary:
    Contributors: Anees Malik and Hristina Ivanova

    The unanimous recommendation by the Oncologic Drugs Advisory Committee (ODAC) for FDA approval of Sandoz’s biosimilar filgrastim (EP2006; Zarxio)–the first biosimilar filing to be accepted in the United States– moves the biosimilar product tantalizingly close to FDA approval. Oncology, Biosimilars, “Anees Malik”, “Hristina Ivanova”

    Decision Resources Group brands include: